Plavix
Formulated to target platelet aggregation, indicated to mitigate the risk of stroke and heart attack.
Strengths: 75mg
Where to Check Availability
Medicine details
- Therapeutic class
Antiplatelet Agent
- Pharmacological class
Thienopyridine Antiplatelet
- Minor side effects
bruising; epistaxis; diarrhoea
- Moderate side effects
gastrointestinal haemorrhage; haematoma; dyspepsia
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
Sanofi
- Onset Time
2 hours
- Duration
7–10 days
- Storage instructions
Store in original packaging.
- Drug interactions
warfarin; omeprazole; aspirin
- Age restrictions
Not for children.
- Pregnancy and breastfeeding
Pregnancy: Not recommended. Breastfeeding: Discontinue use or avoid treatment.
Contraindications
hypersensitivity to clopidogrel; active pathological bleeding; severe hepatic impairment
Precautions and warnings
stop treatment before planned surgery; report any unusual bleeding; monitor for signs of bruising
Serious side effects
thrombotic thrombocytopenic purpura — requires immediate medical attention; intracranial haemorrhage — requires immediate medical attention
Patient summary
Formulated to target platelet aggregation, indicated to mitigate the risk of stroke and heart attack.
Mechanism of action
Clopidogrel is a prodrug that irreversibly inhibits the P2Y12 subtype of ADP receptors on blood platelets. This prevents platelet activation and aggregation, reducing the formation of clots in the bloodstream.
Plavix
Formulated to target platelet aggregation, indicated to mitigate the risk of stroke and heart attack.
Editorial Notes
- Active ingredient(s): Clopidogrel
- Listed indication(s): Atherothrombotic Events, Myocardial Infarction, Stroke
Available option
- 180 tablets - 75 mg601-75-mg-5161